hydroxychloroquine has been researched along with Blood Clot in 66 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sporadic studies suggest hydroxychloroquine (HCQ) may be effective for thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may lead to antiphospholipid antibody (aPL) titer reduction but data from randomized studies are lacking." | 9.34 | The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. ( Koutsogianni, A; Kravvariti, E; Samoli, E; Sfikakis, PP; Tektonidou, MG, 2020) |
| "Objective The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases." | 9.27 | Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. ( Belmont, HM; Branch, DW; Cuadrado, MJ; Erkan, D; Gonzalez, E; Knight, JS; Sciascia, S; Tektonidou, MG; Unlu, O; Uthman, I; Wahl, D; Willis, R; Zhang, Z; Zuily, S, 2018) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 8.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 7.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 6.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 6.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 5.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 5.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| "Sporadic studies suggest hydroxychloroquine (HCQ) may be effective for thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may lead to antiphospholipid antibody (aPL) titer reduction but data from randomized studies are lacking." | 5.34 | The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. ( Koutsogianni, A; Kravvariti, E; Samoli, E; Sfikakis, PP; Tektonidou, MG, 2020) |
| "Objective The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases." | 5.27 | Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. ( Belmont, HM; Branch, DW; Cuadrado, MJ; Erkan, D; Gonzalez, E; Knight, JS; Sciascia, S; Tektonidou, MG; Unlu, O; Uthman, I; Wahl, D; Willis, R; Zhang, Z; Zuily, S, 2018) |
| " Seventy-four patients about to undergo primary unilateral total hip arthroplasty for osteoarthrosis, all receiving a standard thrombosis prophylaxis regime of thigh-length anti-embolic stockings, 5,000 IU heparin delivered subcutaneously twice daily, and 400 mg hydroxychloroquine sulfate delivered twice daily, were entered in a prospective trial." | 5.07 | The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty. ( Bradley, JG; Jager, HJ; Krugener, GH, 1993) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| " Through the dedication and hard work of 50 APS ACTION members, collaborative international projects are currently underway including a multicenter web-based registry and repository of aPL-positive patients, a randomized controlled clinical trial assessing the efficacy of hydroxychloroquine for primary thrombosis prevention in persistently aPL-positive but thrombosis-free patients, standardization of aPL testing through the use of core laboratories worldwide, identification of the limitations in the existing aPL/APS literature, and conducting observational research studies to further our understanding of the disease." | 4.93 | AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. ( Andrade, D; Barbhaiya, M; Erkan, D, 2016) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 4.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 3.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt)." | 3.69 | Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. ( Anderson, G; Barker, JH; Edwards, MH; Harris, EN; Liu, X; Pierangeli, S, 1997) |
| " However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence." | 2.72 | COVID-19 and Its Implications for Thrombosis and Anticoagulation. ( Berkman, SA; Tapson, VF, 2021) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 2.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world." | 2.66 | The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020) |
| "Management of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively." | 2.53 | Current status and future prospects for the treatment of antiphospholipid syndrome. ( Al Marzooqi, A; Al Saleh, J; Khamashta, M; Leone, A, 2016) |
| "Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in the arterial wall." | 2.50 | Anti-inflammatory therapies for cardiovascular disease. ( Lüscher, TF; Ridker, PM, 2014) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 2.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| "Hydroxychloroquine has also been shown to reduce in vivo aPL-induced thrombus formation." | 2.42 | Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. ( Harris, EN; Pierangeli, SS; Vega-Ostertag, M, 2004) |
| "Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge." | 1.72 | Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean. ( Asturkar, V; Bhanu, K; Dorji, T; Hegde, A; Yangzom, S, 2022) |
| "After two months, a systemic lupus erythematosus was diagnosed." | 1.62 | Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus. ( Carvalho, JF; Shoenfeld, Y; Silva, FF, 2021) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 1.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Hydroxychloroquine was found to be linked to a significantly higher live birth rate with respect to the other oral treatments in the Group II patients." | 1.48 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Costedoat-Chalumeau, N; Cuadrado, MJ; De Carolis, S; Gerosa, M; Grandone, E; Haladyj, E; Hoxha, A; Khamashta, MA; Latino, JO; Maina, A; Marozio, L; Mayer-Pickel, K; Mekinian, A; Meroni, PL; Morel, N; Pengo, V; Ramoni, V; Reshetnyak, T; Ruffatti, A; Sciascia, S; Serrano, F; Simchen, MJ; Tenti, S; Tincani, A; Tonello, M; Udry, S, 2018) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 1.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| "Few studies have examined thrombosis in systemic lupus erythematosus (SLE), none have included Asian-Americans, and most have had small sample sizes." | 1.35 | Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. ( Cleveland, CM; Criswell, LA; Kaiser, R, 2009) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (18.18) | 18.7374 |
| 1990's | 3 (4.55) | 18.2507 |
| 2000's | 5 (7.58) | 29.6817 |
| 2010's | 25 (37.88) | 24.3611 |
| 2020's | 21 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Mendoza-Pinto, C | 1 |
| García-Carrasco, M | 1 |
| Munguía Realpozo, P | 1 |
| Méndez-Martínez, S | 1 |
| Hussain, H | 1 |
| Tarantino, MD | 1 |
| Chaturvedi, S | 3 |
| McCrae, KR | 4 |
| Roberts, JC | 1 |
| Dorji, T | 1 |
| Hegde, A | 1 |
| Asturkar, V | 1 |
| Yangzom, S | 1 |
| Bhanu, K | 1 |
| Hubben, A | 1 |
| Arachchillage, DJ | 1 |
| Laffan, M | 2 |
| Pericleous, C | 1 |
| Kravvariti, E | 1 |
| Koutsogianni, A | 1 |
| Samoli, E | 1 |
| Sfikakis, PP | 1 |
| Tektonidou, MG | 5 |
| Zhang, W | 1 |
| Zhao, Y | 1 |
| Zhang, F | 1 |
| Wang, Q | 1 |
| Li, T | 1 |
| Liu, Z | 1 |
| Wang, J | 1 |
| Qin, Y | 1 |
| Zhang, X | 1 |
| Yan, X | 1 |
| Zeng, X | 1 |
| Zhang, S | 1 |
| Doms, J | 1 |
| Horisberger, A | 1 |
| Ribi, C | 1 |
| Besutti, G | 1 |
| Bonacini, R | 1 |
| Iotti, V | 1 |
| Marini, G | 1 |
| Riva, N | 1 |
| Dolci, G | 1 |
| Maiorana, M | 1 |
| Spaggiari, L | 1 |
| Monelli, F | 1 |
| Ligabue, G | 1 |
| Guaraldi, G | 1 |
| Rossi, PG | 1 |
| Pattacini, P | 1 |
| Massari, M | 1 |
| Sciascia, S | 5 |
| Schreiber, K | 2 |
| Radin, M | 2 |
| Roccatello, D | 3 |
| Krämer, BK | 1 |
| Stach, K | 1 |
| Hossri, S | 1 |
| Shadi, M | 1 |
| Hamarsha, Z | 1 |
| Schneider, R | 1 |
| El-Sayegh, D | 1 |
| González-García, A | 1 |
| López-Rodríguez, M | 1 |
| Redondo, S | 1 |
| Patier, JL | 1 |
| Masso, P | 1 |
| Tenorio, M | 1 |
| Fajardo, GS | 1 |
| Sarhane, Y | 1 |
| Lacalzada, MM | 1 |
| Manzano, L | 1 |
| Di Perri, G | 1 |
| Meng, J | 1 |
| Chen, L | 1 |
| Hou, J | 1 |
| Chi, H | 1 |
| Wang, Z | 1 |
| Yang, C | 1 |
| Su, Y | 1 |
| Carvalho, JF | 1 |
| Silva, FF | 1 |
| Shoenfeld, Y | 1 |
| Cohen, H | 2 |
| Cuadrado, MJ | 4 |
| Erkan, D | 4 |
| Duarte-Garcia, A | 1 |
| Isenberg, DA | 1 |
| Knight, JS | 2 |
| Ortel, TL | 2 |
| Rahman, A | 2 |
| Salmon, JE | 2 |
| Williams, DJ | 1 |
| Willis, R | 3 |
| Woller, SC | 1 |
| Andrade, D | 4 |
| Petri, M | 3 |
| Konig, MF | 1 |
| Li, J | 1 |
| Goldman, DW | 1 |
| Devaux, CA | 1 |
| Camoin-Jau, L | 1 |
| Mege, JL | 1 |
| Raoult, D | 1 |
| Berkman, SA | 1 |
| Tapson, VF | 1 |
| Duan, J | 1 |
| Ma, D | 1 |
| Wen, X | 1 |
| Guo, Q | 1 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Xu, K | 1 |
| Zhang, L | 1 |
| Anedda, L | 1 |
| Bianchini, L | 1 |
| Cuzzolin, L | 1 |
| Finco, G | 1 |
| Fanos, V | 1 |
| Marcialis, MA | 1 |
| Arachchillage, DRJ | 1 |
| Unlu, O | 1 |
| Belmont, HM | 1 |
| Branch, DW | 2 |
| Gonzalez, E | 1 |
| Uthman, I | 2 |
| Zhang, Z | 1 |
| Wahl, D | 1 |
| Zuily, S | 1 |
| Ruffatti, A | 2 |
| Tonello, M | 1 |
| Hoxha, A | 1 |
| Latino, JO | 2 |
| Udry, S | 2 |
| Reshetnyak, T | 1 |
| Costedoat-Chalumeau, N | 1 |
| Morel, N | 1 |
| Marozio, L | 1 |
| Tincani, A | 3 |
| Andreoli, L | 2 |
| Haladyj, E | 1 |
| Meroni, PL | 2 |
| Gerosa, M | 1 |
| Alijotas-Reig, J | 2 |
| Tenti, S | 1 |
| Mayer-Pickel, K | 1 |
| Simchen, MJ | 1 |
| Bertero, MT | 1 |
| De Carolis, S | 1 |
| Ramoni, V | 1 |
| Mekinian, A | 1 |
| Grandone, E | 1 |
| Maina, A | 1 |
| Serrano, F | 1 |
| Pengo, V | 1 |
| Khamashta, MA | 2 |
| Belizna, C | 4 |
| Pregnolato, F | 1 |
| Abad, S | 1 |
| Amital, H | 1 |
| Amoura, Z | 1 |
| Andres, E | 1 |
| Aouba, A | 1 |
| Apras Bilgen, S | 1 |
| Arnaud, L | 1 |
| Bienvenu, B | 1 |
| Bitsadze, V | 1 |
| Blanco, P | 1 |
| Blank, M | 1 |
| Borghi, MO | 1 |
| Caligaro, A | 1 |
| Candrea, E | 1 |
| Canti, V | 1 |
| Chiche, L | 1 |
| Chretien, JM | 1 |
| Cohen Tervaert, JW | 1 |
| Damian, L | 2 |
| Delross, T | 1 |
| Dernis, E | 1 |
| Devreese, K | 1 |
| Djokovic, A | 1 |
| Esteve-Valverde, E | 1 |
| Favaro, M | 1 |
| Fassot, C | 1 |
| Ferrer-Oliveras, R | 1 |
| Godon, A | 1 |
| Hamidou, M | 1 |
| Hasan, M | 1 |
| Henrion, D | 3 |
| Imbert, B | 1 |
| Jeandel, PY | 1 |
| Jeannin, P | 1 |
| Jego, P | 1 |
| Jourde-Chiche, N | 1 |
| Khizroeva, J | 1 |
| Lambotte, O | 1 |
| Landron, C | 1 |
| Lazaro, E | 1 |
| de Leeuw, K | 1 |
| Le Gallou, T | 1 |
| Kiliç, L | 1 |
| Limper, M | 1 |
| Loufrani, L | 3 |
| Lubin, R | 1 |
| Magy-Bertrand, N | 1 |
| Mahe, G | 1 |
| Makatsariya, A | 1 |
| Martin, T | 1 |
| Muchardt, C | 1 |
| Nagy, G | 1 |
| Omarjee, L | 1 |
| Van Paasen, P | 1 |
| Pernod, G | 1 |
| Perrinet, F | 1 |
| Pïres Rosa, G | 1 |
| Pistorius, MA | 1 |
| Said, F | 1 |
| Saulnier, P | 1 |
| Sene, D | 1 |
| Sentilhes, L | 1 |
| Shovman, O | 1 |
| Sibilia, J | 1 |
| Sinescu, C | 1 |
| Stanisavljevic, N | 1 |
| Stojanovich, L | 1 |
| Tam, LS | 1 |
| Tollis, F | 1 |
| Ungeheuer, MN | 1 |
| Versini, M | 1 |
| Cervera, R | 1 |
| Urbanski, G | 1 |
| Caillon, A | 1 |
| Poli, C | 1 |
| Kauffenstein, G | 1 |
| Begorre, MA | 1 |
| Miranda, S | 1 |
| Billoir, P | 1 |
| Thiebaut, PA | 1 |
| Schapman, D | 1 |
| Le Besnerais, M | 1 |
| Jouen, F | 1 |
| Galas, L | 1 |
| Levesque, H | 1 |
| Le Cam-Duchez, V | 1 |
| Joannides, R | 1 |
| Richard, V | 1 |
| Benhamou, Y | 1 |
| Schmidt-Tanguy, A | 1 |
| Voswinkel, J | 1 |
| Subra, JF | 1 |
| Rohmer, V | 1 |
| Ifrah, N | 1 |
| Ibáñez, S | 1 |
| Iruretagoyena, M | 1 |
| Gutiérrez, MA | 1 |
| Aguiar, CL | 1 |
| Danowski, A | 1 |
| Levy, RA | 2 |
| Lockshin, MD | 1 |
| Mar, N | 1 |
| Kosowicz, R | 1 |
| Hook, K | 1 |
| Ridker, PM | 1 |
| Lüscher, TF | 1 |
| Merashli, M | 1 |
| Noureldine, MH | 1 |
| Khamashta, M | 3 |
| Middeldorp, S | 1 |
| Pavord, S | 1 |
| Ruiz-Irastorza, G | 1 |
| Hunt, BJ | 1 |
| Tektonidou, M | 1 |
| Al Marzooqi, A | 1 |
| Leone, A | 1 |
| Al Saleh, J | 1 |
| Barbhaiya, M | 1 |
| Bazzan, M | 1 |
| Kaiser, R | 1 |
| Cleveland, CM | 1 |
| Criswell, LA | 1 |
| Laskari, K | 1 |
| Panagiotakos, DB | 1 |
| Moutsopoulos, HM | 1 |
| Jung, H | 1 |
| Bobba, R | 1 |
| Su, J | 1 |
| Shariati-Sarabi, Z | 1 |
| Gladman, DD | 1 |
| Urowitz, M | 1 |
| Lou, W | 1 |
| Fortin, PR | 1 |
| Wallace, DJ | 1 |
| Szymezak, J | 1 |
| Ankri, A | 1 |
| Fischer, AM | 1 |
| Darnige, L | 1 |
| Scoble, T | 1 |
| Wijetilleka, S | 1 |
| Francès, C | 1 |
| Barete, S | 1 |
| Ayoub, N | 1 |
| Piette, JC | 1 |
| BETETTO, D | 1 |
| CRISTINA, P | 1 |
| SPANIO, G | 1 |
| Pierangeli, SS | 1 |
| Vega-Ostertag, M | 1 |
| Harris, EN | 2 |
| Ho, KT | 1 |
| Ahn, CW | 1 |
| Alarcón, GS | 1 |
| Baethge, BA | 1 |
| Tan, FK | 1 |
| Roseman, J | 1 |
| Bastian, HM | 1 |
| Fessler, BJ | 1 |
| McGwin, G | 1 |
| Vilá, LM | 1 |
| Calvo-Alén, J | 1 |
| Reveille, JD | 1 |
| Hansen, MS | 1 |
| Birgens, HS | 1 |
| Turpie, AG | 2 |
| Bradley, JG | 1 |
| Krugener, GH | 1 |
| Jager, HJ | 1 |
| Edwards, MH | 1 |
| Pierangeli, S | 1 |
| Liu, X | 1 |
| Barker, JH | 1 |
| Anderson, G | 1 |
| Hirsh, J | 4 |
| Latour, JG | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Harker, LA | 2 |
| Gent, M | 2 |
| Genton, E | 2 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
| Bounameaux, Y | 1 |
| Jobin, F | 1 |
| Gagnon, FT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144] | 200 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534] | 1,800 participants (Actual) | Observational | 2020-05-29 | Completed | |||
| Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851] | 23 participants (Anticipated) | Observational | 2021-06-10 | Recruiting | |||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| "Constitution d'Une Cohorte Prospective de Sujets Sains et Malades et d'Une Collection de Ressources Biologiques associées Pour l'étude du système Immunitaire et de Ses déterminants Génétiques et Environnementaux"[NCT03925272] | 2,200 participants (Anticipated) | Interventional | 2011-02-02 | Recruiting | |||
| Collection d'échantillons Biologiques Humains de Sujets Sains et Malades Pour la Mise au Point et la Validation de Nouvelles méthodes de Diagnostic et Pour la réalisation d'Expertises Dans le Domaine Des Maladies Infectieuses et Tropicales[NCT03912246] | 800 participants (Actual) | Interventional | 2009-04-27 | Completed | |||
| Perioperative Inflammatory Response Assessment in High-risk Patients Undergoing Noncardiac Surgery - a Prospective Non-interventional Observational Study[NCT04753307] | 1,400 participants (Anticipated) | Observational | 2021-01-19 | Recruiting | |||
| The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206] | Phase 4 | 34 participants (Actual) | Interventional | 2017-11-08 | Completed | ||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| [NCT00005436] | 0 participants | Observational | 1991-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
36 reviews available for hydroxychloroquine and Blood Clot
| Article | Year |
|---|---|
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined | 2021 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydroxychlo | 2022 |
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome.
Topics: Anticoagulants; Antimalarials; Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Humans; Hydro | 2023 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
[Management of the antiphospholipid syndrome in adults].
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydr | 2020 |
Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Ao | 2020 |
Probable catastrophic antiphospholipid syndrome secondary to chronic myelomonocytic leukaemia in an adult patient and a mini review.
Topics: Antiphospholipid Syndrome; Bone Marrow; Computed Tomography Angiography; Humans; Hydroxychloroquine; | 2020 |
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Congresses as Topic; Factor | 2020 |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Antiphospholipid; Antibodies, Monoclo | 2021 |
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Case-Control Studies; Diabetes, Gestational; Female; HE | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antico | 2021 |
Pathogenesis and management of antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Complement Inactiv | 2017 |
Diagnosis and management of the antiphospholipid syndrome.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Disease Management; En | 2017 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
[New alternatives for the treatment of antiphospholipid syndrome. A literature review].
Topics: Agmatine; Antibodies, Monoclonal, Murine-Derived; Antiphospholipid Syndrome; Dipeptides; Glucocortic | 2013 |
14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Factor Xa; Humans; Hydroxyc | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Blood Platelets; Erythrocytes; Hum | 2015 |
Antiphospholipid syndrome: an update.
Topics: Adrenal Cortex Hormones; Animals; Annexin A2; Anticoagulants; Antiphospholipid Syndrome; Drugs, Inve | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
The antiphospholipid syndrome: still an enigma.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta | 2015 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Complement Inactivating Agents; Disease Models, | 2016 |
Current status and future prospects for the treatment of antiphospholipid syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; Female; Humans; Hydroxychloroqui | 2016 |
AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Clinical Trials as To | 2016 |
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antic | 2017 |
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Enzyme Inhibitors; Humans; Hydroxychloroqui | 2011 |
Management of refractory anti-phospholipid syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antiphospholipid Syndrome; Clinical Trials as Topic; Evidenc | 2011 |
Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.
Topics: Animals; Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antiphospholipid Syndrome; Endotheliu | 2004 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
Topics: Antirheumatic Agents; Baltimore; Blood Glucose; Cohort Studies; Diabetes Complications; Diabetes Mel | 1996 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Clinical prevention of thrombosis by antiplatelet agents].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Humans; Hydroxychloroquine; Sulfinpyrazone; Thro | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
7 trials available for hydroxychloroquine and Blood Clot
| Article | Year |
|---|---|
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydr | 2020 |
Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Blood Platelets; Erythrocytes; Femal | 2018 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty.
Topics: Aged; Bandages; Female; Femoral Vein; Foot; Gravity Suits; Heparin; Hip Prosthesis; Humans; Hydroxyc | 1993 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrin | 1975 |
26 other studies available for hydroxychloroquine and Blood Clot
| Article | Year |
|---|---|
Eculizumab for refractory thrombosis in antiphospholipid syndrome.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Aspirin; Clopidogrel; Fema | 2022 |
Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.
Topics: Adult; Antiphospholipid Syndrome; Cyclophosphamide; Female; Humans; Hydroxychloroquine; Immunoglobul | 2022 |
Abdominal Visceral Infarction in 3 Patients with COVID-19.
Topics: Abdomen; Aged; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
Hydroxychloroquine reduces IL-6 and pro-thrombotic status.
Topics: Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Inflammation; Interleukin-6; Lup | 2020 |
Clinically significant anticardiolipin antibodies associated with COVID-19.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiphospholi | 2020 |
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Antiphospholipid Syndrome; Catastrophic Illness; Female; Hepari | 2021 |
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Chromatography, Liquid; Female; Fingers; Gangrene; Humans; Hydroxychlor | 2021 |
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Topics: Administration, Oral; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphosphol | 2018 |
Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome.
Topics: Animals; Antibodies, Anti-Idiotypic; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Disease Model | 2018 |
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Disease Models, Animal; Endothelia | 2019 |
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients.
Topics: Adult; Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Thrombosis | 2013 |
Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.
Topics: Abortion, Spontaneous; Adult; Antiphospholipid Syndrome; Enzyme Inhibitors; Female; Humans; Hydroxyc | 2014 |
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; California; Child; Female; Humans; Hydroxyc | 2009 |
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antirheuma | 2009 |
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middl | 2010 |
Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Thrombosis | 2010 |
[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome].
Topics: Annexin A5; Antiphospholipid Syndrome; Antirheumatic Agents; Biomarkers; Enzyme Inhibitors; Evidence | 2010 |
[Classification of dermatologic manifestations in lupus erythematosus].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Antimalarials; Clinical Trials as Topic; Dapsone; Dermato | 2003 |
[THE USE OF HYDROXYCHLOROQUINE IN THE TREATMENT OF VASCULAR DISEASES].
Topics: Arteriosclerosis; Arteritis; Blood Proteins; Cholesterol; Coronary Disease; Fibrinogen; Humans; Hydr | 1963 |
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.
Topics: Antibodies, Antiphospholipid; Antirheumatic Agents; Epidemiologic Methods; Female; Humans; Hydroxych | 2005 |
[Prevention of thrombosis by thrombocyte inhibitors. 1. Cell regulation mechanisms and pharmacological modification].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Cyclic AMP; Dextrans; Dipyridamole; Humans; Hydroxy | 1980 |
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Dose-Response Relationship, Drug; | 1997 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
[Clinical use of anti-aggregative agents].
Topics: Aspirin; Dipyridamole; Humans; Hydroxychloroquine; Platelet Adhesiveness; Thromboembolism; Thromboph | 1973 |
Platelet reactions and immune processes. IV. The inhibition of complement by pyrazole compounds and other inhibitors of platelet reactions.
Topics: Animals; Blood Coagulation; Blood Platelets; Chloroquine; Complement Inactivator Proteins; Erythrocy | 1970 |